title: Hemolysis upon intravenous immunoglobulin transfusion.
abstract: Intravenous immunoglobulin (IVIG) is a mainstay of therapy in many disorders. An uncommon adverse side effect is IVIG-related hemolysis. Risk factors for IVIG-related hemolysis have been identified, including high dose IVIG given to non-O blood group recipients with an underlying inflammatory state. IVIG-related hemolysis has been linked to anti-A and anti-B hemagglutinins in the IVIG preparations and may involve both IgG and complement mediated hemolysis. A two-hit mechanism with threshold effect is proposed for IVIG-related hemolysis. Strategies exist to minimize or avoid IVIG-related hemolysis.
authors.affiliation: The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6. rpadmore@ottawahospital.on.ca
authors.forename: Ruth F
authors.initials: RF
authors.lastname: Padmore
mesh_terms: D003165:Complement System Proteins / Q000276:immunology / Q000378:metabolism; D006388:Hemagglutinins / Q000097:blood / Q000276:immunology; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D006388:Hemagglutinins; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D003165:Complement System Proteins